Depression

TV News Anchor Kendis Gibson Opens Up About Mental Health Struggles And Psychedelic Therapy In New Memoir
Bitcoin Could Reach $1 Million By 2037, Economist Says: 'Buy Of A Lifetime' Opportunity
The Optimism Experiment: Psilocybin's Impact On Motivation
Bitcoin Could Reach $1 Million By 2037, Economist Says: 'Buy Of A Lifetime' Opportunity
The Optimism Experiment: Psilocybin's Impact On Motivation
Psilocybin Found To Be As Effective As Lexapro In Treating Depression, Researchers Say
New Instagram Study to Investigate Social Media's Effects On Teen Mental Health

Depression Recent News

'Rich Dad Poor Dad' Author Robert Kiyosaki Says 'Soft Landing Is A Fantasy,' Warns Next Crash May Turn Into Depression
This is not the first time Kiyosaki has sounded such an alarm. He has warned of a crash at least four times this year alone.
First Country To Allow MDMA And Psilocybin Mushrooms To Be Prescribed For Depression And PTSD Makes Global Headlines
This article was originally published on Psychedelic Spotlight and appears here with permission.
USPSTF Stands By Depression Screening But Still Omits Suicide Risk Amid Rising Rates: STAT News
Can You Treat Depression With Cannabis? It's Complicated
This article was originally published on Cannabis.net and appears here with permission.
Depression Treatment Breakthrough: The Return Of LSD In Modern Medicine
This article was originally published on Microdose Psychedelic Insights and appears here with permission.
Psychedelics Biotech Company Raises $39M To Develop Next-Gen Treatment For Depression
Psychedelics biotech company Gilgamesh Pharmaceuticals announced the closing of a $39 million Series B financing round led by Prime Movers Lab and joined by Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital and Gron Ventures. 
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc.
Can Ketamine Treat Alcohol Addiction? The Awakn Approach
(Part three of a four-part series)
Thai Government Developing Psychedelic Medicine To Treat Various Mental Health Issues, Including Depression
In the face of the national -and worldwide- mental health crisis, the Thailand National Narcotics Control Board recently announced it will commence developing therapeutics extracted from or based on “magic mushrooms” for treating several mental health conditions, including depression, alcohol addiction and insomnia.
Is Elon Musk Into Psychedelics? Here's What The Tesla CEO Had To Say
The push to legalize psychedelics in more states may have gotten a new public supporter, with the world’s richest man sharing his thoughts and opinions on the benefits.
Cannabis May Ease Depression And Anxiety Long-Term According To Recent Canadian Study
In a recent study on 7,362 adults, Canadian researchers found that cannabis use improved depression and anxiety at 12 and 18 months in adults diagnosed with depression and anxiety long term.  
Canadian Senator Uses This Unconventional Method To Fight Depression, And Meet His Wife While You're Here
If I asked you to picture someone who uses mushrooms (psilocybin), you would not imagine Larry Campbell, a 74-year-old Canadian Senator who has been in politics for two decades.
Field Trip Launches At-Home Ketamine Treatment In Partnership With Nue Life
Field Trip Health (NASDAQ: FTRP), a company offering mental health treatment using ketamine therapy, has inked a unique deal with Nue Life Health to expand its service offerings to at-home treatment.
People With These Disorders May Be More Likely To Overuse Cannabis, Finds Study
This article was originally published on The Fresh Toast and appears here with permission.
Top 5 Most Influential Psychedelic Studies
Reflections On The Headspace Of Mental Health, Magic Mushrooms And Blockchain
This article was originally published on Gokhshtein Media and appears here with permission.
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing 
The Case For Psilocybin Therapy And Depression
This article was originally published on The Bluntness and appears here with permission. Depression is one of the most widespread and difficult to treat mental illnesses on the planet. 
Ketamine Rapidly Reduces Depression, According To 'Most Comprehensive Review' Of Evidence — But Patient Experiences Suggest More Applications
This article was originally published on Psychedelic Spotlight and appears here with permission.
ATAI Life Sciences Announces New Program To Discover Next-Generation Mental Health Treatments
atai Life Sciences (NASDAQ: ATAI) on Thursday announced Invyxis, a new program to accelerate the company’s portfolio of compounds.
Two-Thirds Of Physicians Say Psilocybin Therapy Can Help Treatment-Resistant Depression, New Survey Shows
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) and Sermo announced on Wednesday findings from a survey of Sermo physician members that showed two-thirds of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients w
EXCLUSIVE: Pasithea Expands Its Footprint With Second Ketamine Therapy Clinic In UK
Pasithea Therapeutics Corp's (NASDAQ: KTTA) subsidiary, Pasithea Clinics, has opened its second London clinic in Marylebone, offering intravenous (IV) ketamine therapy to patients suffering from treatment-resistant mental health issues.
Compass Pathways' Psilocybin Therapy Shows Mixed Results From Depression Trial

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved